Major gene study uncovers secrets of leukemia

Mar 07, 2007

Investigators at St. Jude Children's Research Hospital have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia (ALL), the most common cancer in children. The discovery not only suggests novel methods for treating pediatric ALL, but also provides a roadmap for the identification of unsuspected mutations in adult cancers.

ALL is a tumor in which immature white blood cells that normally develop into immune system cells, called B or T lymphocytes, instead multiply rapidly and overwhelm the normal blood cells the body needs to survive.

The St. Jude team used microarrays, postage-stamp-sized chips that contain DNA fragments, which allowed researchers to investigate more than 350,000 markers called single nucleotide polymorphisms. Single nucleotide polymorphisms are individual variations in the DNA that are spaced across the human chromosomes. Single nucleotide polymorphisms function as flags for researchers, allowing them to detect specific deletions of DNA in a gene or increases in the number of specific genes at a level of detail that was previously unattainable. The St. Jude group used this approach to analyze leukemia samples from 242 pediatric patients with ALL. This identified an unexpectedly high frequency of mutations involving genes that function as master regulators of normal B-cell development and differentiation.

A report on this work appears in the March 7 online edition of Nature.

"The results of our study demonstrate that it is possible to significantly speed the identification of the genetic lesions that are the underlying cause of not only ALL, but also many other cancers, including those affecting adults," said James Downing, M.D., scientific director and chair of the Pathology department at St. Jude. He is senior author of the paper.

The study found that 40 percent of patients with ALL had deletions or mutations in one of three so-called "master genes" that control the normal differentiation of immature progenitor cells into mature B lymphocytes.

The researchers found that the "PAX5" gene was most frequently mutated—altered in about 30 percent of patients. These mutations reduced the level of PAX5 protein in leukemic cells or resulted in the formation of PAX5 protein with defective function. Mutations were also found in other genes with important roles in B-cell differentiation including "EBF1" and "Ikaros."

"Although the identification of such a high frequency of mutations in this pathway was surprising, it is important to note that the approach used provides a lower limit of the true frequency of these mutations, since not every gene in this pathway could be accurately analyzed using this methodology," Downing said.

The mutations identified in "PAX5," "EBF" and "Ikaros" are likely to directly contribute to this block in normal lymphocyte differentiation, according to Downing. These genes encode proteins called transcription factors, which orchestrate the expression of a large number of other genes involved in B cell development. Together these genes coordinate the complex changes needed to induce progenitor cells to differentiate into B lymphocytes. In ALL, the leukemic cells fail to differentiate normally and instead remain blocked at an immature stage of development. Locked in this state, the leukemic cells continue to proliferate, and this continual growth of leukemic cells eventually kills the child.

"The new insights into the differentiation of B cells are extremely valuable," said Ching-Hon Pui, M.D., chair of the Oncology department and American Cancer Society Professor at St. Jude. Pui co-authored the paper. "The more we learn about why progenitor cells get stuck in the primitive, cancerous stage, the more likely we'll be able to design new therapies that eliminate them. That could help us continue our successful efforts to increase the survival rate of ALL."

One potential strategy for eliminating leukemic cells would take advantage of the discovery that mutations in the B-cell differentiation pathway are predicted to prevent progenitors from changing into normally functioning lymphocytes. Normally, the body eliminates differentiated B lymphocytes that have failed to assemble the right genes to make effective antibodies against the specific target they are supposed to attack. However, if these defective B lymphocytes do not differentiate because of the mutations, the body will not recognize them as defective immune cells and destroy them. Instead, these undifferentiated cells continue to multiply, causing ALL.

"If we could design a drug that bypasses the roadblock to differentiation, we could push these cells to become fully mature B lymphocytes," Downing said. "And then the body would recognize them as defective B lymphocytes and destroy them."

Source: St. Jude Children's Research Hospital

Explore further: Distinctive developmental origin for a drainage tube in the eye

add to favorites email to friend print save as pdf

Related Stories

Chemists eye improved thin films with metal substitution

16 minutes ago

The yield so far is small, but chemists at the University of Oregon have developed a low-energy, solution-based mineral substitution process to make a precursor to transparent thin films that could find use ...

Recommended for you

Scientists image a beating heart in 3D (w/ Video)

just added

Researchers of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden report how they managed to capture detailed three-dimensional images of cardiac dynamics in zebrafish. The novel approach: ...

New device to monitor lung function in space

8 minutes ago

A new method of collecting blood from the ear, currently part of an interactive exhibition at the Science Museum, could be used to monitor lung function in space. Less invasive, faster and more accurate than current methods, ...

Primate research center plays key role in HIV study in Nature

10 minutes ago

In a study reported in Nature this month, Yerkes National Primate Research Center researchers were key in determining that treating SIV-infected rhesus macaques with type 1 interferon, a protein known to trigger antiviral respon ...

Three-people IVF debate process on the move in UK

2 hours ago

Takes two to make a child, correct? No. maybe. The use of sperm and eggs from three people to create babies moved a step closer in the UK, with Tuesday's events. What kind of egg-sperm distribution are we talking about? The ...

User comments : 0